Performance of the H2FPEF and the HFA-PEFF scores for the diagnosis of heart failure with preserved ejection fraction in Japanese patients: A report from the Japanese multicenter registry

Tada, Atsushi; Nagai, Toshiyuki; Omote, Kazunori; Iwano, Hiroyuki; Tsujinaga, Shingo; Kamiya, Kiwamu; Konishi, Takao; Sato, Takuma; Komoriyama, Hirokazu; Kobayashi, Yuta; Takenaka, Sakae; Mizuguchi, Yoshifumi; Sato, Tomoya; Yamamoto, Keiji; Yoshikawa, Tsutomu; Saito, Yoshihiko; Anzai, Toshihisa

doi:10.1016/j.ijcard.2021.08.001

Cited by 18 publications

(23 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Here, obesity (defined as BMI ≥ 30 kg/m 2 ) is allocated 2 points, increasing the possibility of HFpEF diagnosis in obese patients. Several community-based studies, including those from Asia, have demonstrated acceptable diagnostic and prognostic yields of the H 2 FPEF scoring system [9,10]. However, the appropriate BMI cutoff value for Asian populations, who have a lower BMI than Western populations, should be investigated separately.…”

Section: Diagnostic Approachmentioning

confidence: 99%

Obesity-related heart failure with preserved ejection fraction: diagnostic and therapeutic challenges

Jung

Shin

2023

Korean J Intern Med

View full text Add to dashboard Cite

The prevalence of heart failure with preserved ejection fraction (HFpEF) has increased in recent decades. In particular, obesity-related HFpEF is a distinct and frequently encountered phenotype; however, its diagnosis is complex. Furthermore, the management of obesity-related HFpEF has not been established despite the introduction of promising drugs. This review summarizes the diagnostic challenges, pathophysiology, and therapeutic options for obesity-related HFpEF.

show abstract

Section: Diagnostic Approachmentioning

confidence: 99%

Obesity-related heart failure with preserved ejection fraction: diagnostic and therapeutic challenges

Jung

Shin

2023

Korean J Intern Med

View full text Add to dashboard Cite

show abstract

“… 20 The HFA‐PEFF score is more complicated and evaluates natriuretic peptide levels and echocardiographic findings of cardiac function and structure. 16 Both appear to have diagnostic and prognostic value, 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 although H 2 FPEF may be better at predicting exercise intolerance. 32 Recently, the HFA‐PEFF score was used to identify 4 distinct phenogroups in “early‐HFpEF” patients of increasing severity: (1) no LV diastolic dysfunction, (2) LV diastolic dysfunction with functional LV abnormalities; (3) LV diastolic dysfunction with functional and structural LV abnormalities, and (4) LV diastolic dysfunction with functional and structural LV abnormalities and elevated B‐type natriuretic peptide.…”

Section: Clinical Aspectsmentioning

confidence: 99%

Genomic, Proteomic, and Metabolic Comparisons of Small Animal Models of Heart Failure With Preserved Ejection Fraction: A Tale of Mice, Rats, and Cats

Smith

Altara

Amin

et al. 2022

JAHA

View full text Add to dashboard Cite

Heart failure with preserved ejection fraction (HFpEF) remains a medical anomaly that baffles researchers and physicians alike. The overall phenotypical changes of diastolic function and left ventricular hypertrophy observed in HFpEF are definable; however, the metabolic and molecular alterations that ultimately produce these changes are not well established. Comorbidities such as obesity, hypertension, and diabetes, as well as general aging, play crucial roles in its development and progression. Various animal models have recently been developed to better understand the pathophysiological and metabolic developments in HFpEF and to illuminate novel avenues for pharmacotherapy. These models include multi‐hit rodents and feline aortic constriction animals. Recently, genomic, proteomic, and metabolomic approaches have been used to define altered signaling pathways in the heart associated with HFpEF, including those involved in inflammation, cGMP‐related, Ca 2+ handling, mitochondrial respiration, and the unfolded protein response in endoplasmic reticulum stress. This article aims to present an overview of what has been learnt by these studies, focusing mainly on the findings in common while highlighting unresolved issues. The knowledge gained from these research models will not simply be of benefit for treating HFpEF but will undoubtedly provide new insights into the mechanisms by which the heart deals with external stresses and how the processes involved can fail.

show abstract

“…Such an approach simplifies and standardizes HFpEF diagnosis, but it is not without controversy, garnering criticisms ranging from oversimplification of disease heterogeneity to misclassification particularly in patients with low H 2 FPEF score (Ho et al, 2020;Churchill et al, 2021;Sanders-van Wijk et al, 2021). Nevertheless, the H 2 FPEF scoring algorithm has been validated in various patient cohorts (Packer et al, 2020;Churchill et al, 2021;Faxen et al, 2021;Tada et al, 2021) and its proven prognostic utility in human (Sueta et al, 2019;Parcha et al, 2021) further suggests that it sufficiently identifies key pathophysiologic determinants of HFpEF outcomes. Thus, the H 2 FPEF scoring system may be adapted as a novel standard to assess the clinical applicability and translational value of various pre-clinical HFpEF models.…”

Section: Approach To Validating Hfpef Modelsmentioning

confidence: 99%

Modeling heart failure with preserved ejection fraction in rodents: Where do we stand?

Chou

Chin

2022

Front. Drug. Discov.

View full text Add to dashboard Cite

Heart failure (HF) with preserved ejection fraction (HFpEF) is a clinical syndrome characterized by signs and symptoms of HF in the presence of a normal left ventricular systolic function. Over the past decade, HFpEF has become increasingly prevalent, accounting for greater than 50% of all clinical HF presentations. HFpEF is a complex disease with heterogeneous clinical presentations and multiple non-cardiac comorbidities, which frequently co-exist and contribute to its pathophysiology. To date, only a handful of therapies have been proven to improve, albeit marginally, the outcomes in HFpEF. The development of effective therapeutic agents is in part hampered by the lack of animal models that adequately recapitulate human HFpEF. Although numerous pre-clinical models developed over the years have been labeled as “HFpEF” specific, there has not been a consensus on the appropriate standards for pre-clinical HFpEF models. Thus, the extent to which they truly mirror human HFpEF cannot be systematically validated. Recently, a new algorithm (H2FPEF) was developed to standardize the clinical diagnosis of HFpEF. In this review, with the aid of the clinical H2FPEF scoring system, we evaluate the clinical applicability and translational values of various murine models of HFpEF.

show abstract

Performance of the H2FPEF and the HFA-PEFF scores for the diagnosis of heart failure with preserved ejection fraction in Japanese patients: A report from the Japanese multicenter registry

Cited by 18 publications

References 24 publications

Obesity-related heart failure with preserved ejection fraction: diagnostic and therapeutic challenges

Obesity-related heart failure with preserved ejection fraction: diagnostic and therapeutic challenges

Genomic, Proteomic, and Metabolic Comparisons of Small Animal Models of Heart Failure With Preserved Ejection Fraction: A Tale of Mice, Rats, and Cats

Modeling heart failure with preserved ejection fraction in rodents: Where do we stand?

Contact Info

Product

Resources

About